
METABOLIC DISORDERS
Health-related QoL in osteoporotic women improved with zoledronic acid infusions
Bone. 2011 Jun 1;48(6):1298-304. doi: 10.1016/j.bone.2011.03.719. Epub 2011 Mar 21This study included a subset of 1434 participants from the Health Outcomes and Reduced Incidence with Zoledronic acid ONce yearly (HORIZON) Pivotal Fracture Trial, examining the effect of zoledronic acid on health-related quality of life in postmenopausal, osteoporotic women. After 3 years of follow-up, participants treated with annual infusions of zoledronic acid displayed a significant improvement in various domains of health-related quality of life when compared to those treated with placebo infusions.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in


Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now